ORG Partners LLC Grows Holdings in Amgen Inc. (NASDAQ:AMGN)

ORG Partners LLC raised its stake in Amgen Inc. (NASDAQ:AMGN) by 4.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,741 shares of the medical research company’s stock after acquiring an additional 332 shares during the quarter. ORG Partners LLC’s holdings in Amgen were worth $2,230,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Briaud Financial Planning Inc bought a new stake in shares of Amgen in the third quarter valued at approximately $26,000. OFI Invest Asset Management bought a new position in shares of Amgen in the 3rd quarter worth $26,000. Planned Solutions Inc. bought a new position in shares of Amgen in the 4th quarter worth $30,000. Providence Capital Advisors LLC bought a new position in shares of Amgen in the 3rd quarter worth $30,000. Finally, Hartford Financial Management Inc. boosted its stake in shares of Amgen by 56.9% in the 4th quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 41 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Down 1.0 %

NASDAQ AMGN traded down $2.72 during trading on Friday, hitting $267.28. The company had a trading volume of 2,140,106 shares, compared to its average volume of 2,899,748. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The company has a market cap of $143.24 billion, a price-to-earnings ratio of 21.40, a price-to-earnings-growth ratio of 2.52 and a beta of 0.58. The company’s fifty day moving average is $280.76 and its 200-day moving average is $281.38.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same period in the prior year, the business earned $4.09 EPS. On average, sell-side analysts predict that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.37%. Amgen’s payout ratio is 72.06%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $350.00 price objective on shares of Amgen in a research note on Thursday, February 1st. Raymond James assumed coverage on shares of Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating for the company. StockNews.com cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Thursday, March 28th. UBS Group cut their price objective on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a research note on Monday, January 29th. Finally, SVB Leerink cut shares of Amgen from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $295.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.